18 July 2016
Today DoseMe announced a strategic alliance with specialist oncology eHealth provider, Charm Health, to integrate its personalised dosing tool with the CHARM™ platform. This will provide clinicians using CHARM with immediate access to the DoseMe library of individualised dosing models, significantly enhancing their clinical decision-making in the complex area of dose adjustment of chemotherapy and other medicines used in cancer care.
For many medicines used in the care of cancer patients, the difference between an effective dose and a toxic dose is very small; making accurate dose calculations is a critical, and challenging, aspect of care. Historically, dosing recommendations have been based on population research but cancer patients vary greatly in both their response to treatment, and their ability to metabolise drugs. The ability to individualise a patient’s dose, based on their personal characteristics and response to treatment offers a major leap forward in helping clinicians achieve improved response and outcomes for cancer patients.
DoseMe is an Australian founded digital medical solution that allows clinicians to dose a patient based on their individual ability to absorb, metabolise, distribute and eliminate a therapeutic drug. Using more than basic information such as age, weight, dose administered, and previous response to therapy, DoseMe can quickly and accurately calculate the most effective dose to reach a desired therapeutic target based on the metabolism of the patient. In addition, DoseMe can incorporate laboratory test results and continue to learn over time; continuously becoming more refined in its dose recommendations.
Charm Health is Australia’s leading developer and supplier of specialist oncology information management systems, supporting the delivery of more efficient, cost effective and safer health care services in the complex medical environment of cancer care. The standardised care pathway templates in the CHARM library are built on evidence-based research. Decision support within CHARM guides clinicians in adapting pathway templates to the clinical context of individual patients.Availability of the DoseMe personalised dosing function within the CHARM application will extend the range of decision support tools available to guide clinicians in tailoring treatment and care for each individual patient.
There are natural synergies between DoseMe and Charm Health that will nurture a strong and productive relationship. The companies have a shared origin as ‘startups’ that were established to deliver practical solutions to real-life problems in health care and have continued to put patient care and outcomes at the forefront of their innovations. Both headquartered in Brisbane, DoseMe and Charm Health are among the very few medical software vendors operating in Australia that have registered their products as ‘medical devices’ with the Therapeutic Goods Administration.
The focus of the collaboration is on delivering better outcomes for cancer patients. DoseMe enables clinicians to quickly and accurately determine the right dose for each individual patient. Working with CHARM to present the information in a readily consumable format, clinicians will be able to leverage the DoseMe platform as part of their current workflows. Ultimately, this partnership is aimed at supporting clinicians with information to make the best possible decisions for patient care.
Charles Cornish, Chief Executive Officer of DoseMe said; “Charm Health is an amazing organisation that has never lost sight of its primary purpose which is to support the care team to make a cancer patient’s journey and outcomes the best that they can be. I have admired their approach to business and swift growth in recent years. As the powerhouse in the oncology space, not only could our partnership improve patient outcomes, but possibly adjust future treatment guidelines. In the past decade over 65,000 patients have had their cancer treatment managed by Charm Health solutions. Charm Health’s deep experience combined with DoseMe data analytics will allow us to work with clinics to proactively determine tighter dosing guidelines and maybe even uncover better treatment regimens previously not considered”
“Although we are both software companies, we have a duty to leverage our research and development strengths for the greater good. Both DoseMe and Charm Health are committed to that greater good, which makes the working relationship so well aligned”, Mr Cornish said.
Gary Lakin, Chief Executive Officer of Charm Health, said: “We are excited to partner with a fellow Queensland innovator to enhance our offering to the CHARM community of users. The cutting edge technology presented by DoseMe has the potential to revolutionise the way chemotherapy and other oncology medicines are dosed. Clinicians using CHARM already benefit from the evidence based pathways library and existing decision support available within CHARM but ‘personalised dosing’ is a quantum leap in terms of the level of confidence that clinicians will have in managing the medication care of an individual patient. Together we are leading the way to ‘precision medicine’ in cancer care”. “We are a proud Australian company with an intimate understanding of the Australian healthcare environment. Working with DoseMe is an opportunity for two ‘Australian Made’ companies to enhance our contribution to cancer patients and the Australian healthcare industry”, Mr Lakin said.
DoseMe is the first predictive personalised dosing platform cleared by the Therapeutic Goods Administration for use in Australia to support clinicians in improving patient outcomes through precision dosing. Pairing complex algorithms with a simple, app-based user interface allows a clinician to get the right dose every time. DoseMe supports several classes of drugs that are available on the Charm Health platform, including chemotherapeutic agents, immunosuppressants, antibiotics, anti-coagulants, and Factor VII.
About Charm Health
Charm Health is Australia’s leading supplier of specialist oncology eHealth systems with over 50 successful deployments to Australian public and private cancer care providers since 2000. In the past decade over 65,000 patients have had their treatment managed using Charm Health solutions. Charm Health’s flagship product CHARM™ delivers comprehensive multi-site functionality that manages the clinical and administrative coordination of all aspects of a patient’s cancer care. Charm Health solutions mitigate compliance, clinical, financial and administrative risk by ensuring the most up to date patient information is available to all health care providers, in real time, when making important clinical and prescribing decisions.
Charm Health is a portfolio company of the OneVentures Innovation Fund.
Read more about Charm Health at: Charm Health
Read more about DoseMe: DoseMe
For more information and/interviews:
Marketing Communications Manager, DoseMe
M: 0421 046 279
Chief Executive Officer, Charm Health
M: 0400 808 504
Posted in — Media Release